



SARS-CoV-2 Serological Studies around the Globe

Guest Editors:

Prof. Dr. Angelos Hatzakis

1. Department of Hygiene,
Epidemiology and Medical
Statistics, Medical School,
National and Kapodistrian
University of Athens, 11527
Athens, Greece

2. Hellenic Scientific Society for
the Study of AIDS, Sexually
Transmitted and Emerging
Diseases, 11527 Athens, Greece

Prof. Dr. Dimitrios Paraskevis

Department of Hygiene,
Epidemiology and Medical
Statistics, Medical School,
National and Kapodistrian
University of Athens, 11527
Athens, Greece

Deadline for manuscript
submissions:

closed (31 May 2021)

Message from the Guest Editors

Dear Colleagues,

A novel coronavirus (2019-nCoV) associated with human to human transmission and severe human infection has been recently reported. Given the high transmissibility and the extensive geographic dispersal of the virus as well as the absence of effective treatments or a vaccine, public health measures provide the only way to prevent SARS-CoV-2 transmission. Given that SARS-CoV-2 is a new virus, we need to better understand the levels and the duration of protective immunity in patients with different severities of the disease (i.e., asymptomatic, mild and severe symptoms, hospitalized patients, ARDS symptoms), the levels of exposure to SARS-CoV-2 in highly vulnerable people and populations of special interest (i.e., healthcare workers, migrants, intravenous drug users, populations with limited access to health care facilities, HIV/AIDS patients), the parameters associated with the presence of antibodies, as well as the estimated performance of antibody testing in panels with known SARS-CoV-2 status. All of this information will be valuable across different geographic areas and different time periods.

Prof. Angelos Hatzakis

Dr. Dimitrios Paraskevis

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com